| High grade B-cell lymphoma
Yescarta vs Epkinly
Side-by-side clinical, coverage, and cost comparison for high grade b-cell lymphoma.Deep comparison between: Yescarta vs Epkinly with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpkinly has a higher rate of injection site reactions vs Yescarta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epkinly but not Yescarta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Yescarta
Epkinly
At A Glance
IV infusion
Single infusion
CD19-directed CAR T cell immunotherapy
SC injection
Every 1-4 weeks
CD20xCD3 bispecific antibody
Indications
- Diffuse Large B-Cell Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Lymphoma, Follicular
Dosing
Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, High grade B-cell lymphoma Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Lymphoma, Follicular Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (monotherapy) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg every 2 weeks for Cycles 4-9; 48 mg monthly from Cycle 10 until disease progression or unacceptable toxicity.
Lymphoma, Follicular (+ lenalidomide and rituximab) Step-up SC doses: 0.16 mg (Day 1), 0.8 mg (Day 8), 3 mg (Day 15); then 48 mg weekly through Cycle 3; 48 mg monthly for Cycles 4-12 with lenalidomide 20 mg (Days 1-21) and rituximab 375 mg/m2 (Cycles 1-5); total 12 cycles or until progression.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) CRS, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections with pathogen unspecified, chills, decreased appetite
Serious CRS, fever, encephalopathy, hypotension, infection with unspecified pathogen, pneumonia, febrile neutropenia, cardiac arrhythmia, cardiac failure, aphasia, hypoxia
Postmarketing Spinal cord edema, myelitis, quadriplegia, dysphagia, status epilepticus, infusion related reactions, T cell malignancies
Most common (>=20%) CRS, fatigue, injection site reactions, musculoskeletal pain, pyrexia, abdominal pain, nausea, diarrhea, rash, upper respiratory tract infections, constipation, pneumonia, COVID-19, fever, cough, headache
Serious CRS, infections (sepsis, COVID-19, pneumonia, upper respiratory tract infections), pleural effusion, febrile neutropenia, fever, ICANS
Postmarketing Hemophagocytic Lymphohistiocytosis (HLH)
Pharmacology
CD19-directed genetically modified autologous T cell immunotherapy; upon engagement with CD19-expressing target cells, the CD28 and CD3-zeta co-stimulatory domains activate downstream signaling cascades leading to T cell activation, proliferation, and killing of CD19-expressing cancer cells and normal B cells.
Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager (humanized IgG1) that simultaneously binds CD3 on T-cells and CD20 on lymphoma and healthy B-lineage cells, activating T-cells, inducing cytokine release, and causing B-cell lysis; in combination with rituximab it also mediates NK cell antibody-dependent cellular cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Yescarta
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Epkinly
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Yescarta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Epkinly
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Yescarta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Epkinly
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGenmab Patient Assistance Program: Epkinly
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
YescartaView full Yescarta profile
EpkinlyView full Epkinly profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.